Health Care & Life Sciences » Biotechnology | Sorrento Therapeutics Inc.

Sorrento Therapeutics Inc. | Mutual Funds

Mutual Funds that own Sorrento Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
SPDR S&P Biotech ETF
6,052,914
5.19%
15,789
0.56%
09/06/2018
iShares Russell 2000 ETF
1,819,473
1.56%
-972
0.02%
09/06/2018
Vanguard Total Stock Market Index Fund
1,708,001
1.46%
0
0%
07/31/2018
Vanguard Extended Market Index Fund
1,216,825
1.04%
240,755
0.01%
07/31/2018
iShares Russell 2000 Growth ETF
846,250
0.73%
0
0.04%
09/06/2018
Vanguard Strategic Small Cap Equity Fund
812,751
0.7%
375,288
0.23%
06/30/2018
PowerShares DWA Healthcare Momentum Portfolio
699,997
0.6%
33,333
1.26%
09/05/2018
651,690
0.56%
651,690
2.76%
03/31/2018
Fidelity Spartan Extended Market Index Fund
417,352
0.36%
78,162
0.01%
07/31/2018
327,610
0.28%
0
3.08%
09/06/2018

About Sorrento Therapeutics

View Profile
Address
4955 Directors Place
San Diego California 92121
United States
Employees -
Website http://www.sorrentotherapeutics.com
Updated 07/08/2019
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. The company was founded by Henry H.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.